Key takeaways
Vumerity (diroximel fumarate) and glatiramer (Copaxone) are both used to treat relapsing forms of multiple sclerosis (MS), but they have some key differences. Vumerity is taken orally twice a day, while glatiramer is injected under the skin either daily or three times a week, depending on the dose. Vumerity is a fumaric acid derivative and its exact mechanism is unknown, but it is thought to work through the Nrf2 pathway to reduce inflammation. On the other hand, glatiramer is a disease-modifying therapy that likely works by blocking certain immune system processes. Common side effects of Vumerity include flushing and stomach upset, while glatiramer often causes injection site reactions like redness and pain. Additionally, Vumerity has dietary restrictions and should not be taken with high-fat, high-calorie meals, whereas glatiramer requires careful rotation of injection sites to avoid skin damage. Vumerity is only available as a brand-name medication, which can be expensive, whereas glatiramer is available as a lower-cost generic.
